Pascale Guitera Selected Research

Melanoma (Melanoma, Malignant)

12/2022	Perspectives and Experiences of Patient-Led Melanoma Surveillance Using Digital Technologies From Clinicians Involved in the MEL-SELF Pilot Randomized Controlled Trial: Qualitative Interview Study.
5/2022	Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanoma.
1/2022	Assessing the Potential for Patient-led Surveillance After Treatment of Localized Melanoma (MEL-SELF): A Pilot Randomized Clinical Trial.
10/2021	Skin cancer classification via convolutional neural networks: systematic review of studies involving human experts.
5/2021	Can patient-led surveillance detect subsequent new primary or recurrent melanomas and reduce the need for routinely scheduled follow-up? A protocol for the MEL-SELF randomised controlled trial.
1/2021	Efficiency of Detecting New Primary Melanoma Among Individuals Treated in a High-risk Clinic for Skin Surveillance.
1/2018	Patient Preferences for Follow-up After Recent Excision of a Localized Melanoma.
1/2018	Use of shared care and routine tests in follow-up after treatment for localised cutaneous melanoma.
11/2017	Fear of new or recurrent melanoma after treatment for localised melanoma.
8/2014	Detection of primary melanoma in individuals at extreme high risk: a prospective 5-year follow-up study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Pascale Guitera Research Topics

Disease

11	Melanoma (Melanoma, Malignant) 12/2022 - 08/2010
4	Hutchinson's Melanotic Freckle (Lentigo Maligna) 07/2022 - 01/2018
4	Neoplasms (Cancer) 01/2022 - 08/2010
2	Skin Neoplasms (Skin Cancer) 01/2022 - 10/2021
1	Adenocarcinoma 09/2022
1	Complementation Group D1 Fanconi Anemia 09/2022
1	Hyperpigmentation 07/2022
1	Inflammation (Inflammations) 01/2022
1	Basal Cell Carcinoma (Rodent Ulcer) 01/2022
1	Nevus (Nevi) 08/2010
1	Neoplasm Metastasis (Metastasis) 08/2010

Drug/Important Bio-Agent (IBA)

2	Immune Checkpoint InhibitorsIBA 05/2022 - 01/2022
2	Imiquimod (Aldara)FDA LinkGeneric 01/2022 - 11/2021
2	tributyl phosphate (TBP)IBA 01/2021 - 08/2014
1	MetalsIBA 07/2022
1	Proteins (Proteins, Gene)FDA Link 01/2022
1	Toll-Like Receptor AgonistsIBA 01/2022
1	Biomarkers (Surrogate Marker)IBA 10/2021
1	Protons (Proton)IBA 08/2010
1	Choline (Choline Chloride)IBA 08/2010
1	N 30IBA 08/2010

Therapy/Procedure

5	Aftercare (After-Treatment) 05/2022 - 11/2017
4	Ambulatory Care (Outpatient Care) 12/2022 - 01/2018
3	Therapeutics 05/2022 - 01/2022
1	Drug Therapy (Chemotherapy) 09/2022
1	Tattooing 07/2022
1	Dermatologic Surgical Procedures 01/2022
1	Immunotherapy 01/2022
1	Radiotherapy 01/2018